


OUR RESEARCH PORTFOLIO AT A GLANCE



2018 – 2019 Fiscal Year

REGIONAL NODES



BC	AB	PRAIRIES	ON	QC	ATLANTIC
\$9.2M INVESTED	\$500K INVESTED	\$100K INVESTED	\$12.6M INVESTED	\$3.4M INVESTED	\$800K INVESTED
21 PROJECTS*	6 PROJECTS*	2 PROJECTS*	31 PROJECTS*	11 PROJECTS*	7 PROJECTS*
103 RESEARCHERS	20 RESEARCHERS	5 RESEARCHERS	189 RESEARCHERS	105 RESEARCHERS	13 RESEARCHERS
16 INSTITUTIONS	10 INSTITUTIONS	5 INSTITUTIONS	22 INSTITUTIONS	23 INSTITUTIONS	10 INSTITUTIONS

**Many of our projects are pan-Canadian in nature and their research is conducted in more than one region. Thus, project totals shown here should not be added up, as their sum will equal more than 47, the total number of projects we fund.*

FUNDING PROGRAMS


Program	Investment	Projects	Researchers
Terry Fox New Frontiers Program Project Grants	\$16.5M	18	190
Terry Fox Translational Research Program	\$6.2M	9	208
Terry Fox New Investigator Award	\$1.3M	13	17
Marathon of Hope Cancer Centres Network Pilots	\$1.9M	2	81
Terry Fox Cancer Research Training Program	\$515K	4	6
Other Programs	\$100K	1	2
Total	\$26.6M	47	435*

**A number of researchers work on several projects across program types. While these individuals may be counted in more than one program type, the total number displayed at the bottom reflects the individual number of researchers we fund: 435*

CANCER TYPES[†]

Investment by Cancer Type

● Blood	\$4.3M
● Prostate	\$4.3M
● Pediatric & Young Adult	\$2.7M
● Ovarian	\$2.4M
● Brain	\$1.9M
● Rare Cancers	\$1.8M
● Breast	\$1.7M
● Pancreatic	\$1.3M
● Lung	\$1.2M
● Colorectal	\$1.1M
● Other*	\$3.9M




*This category includes our investment in projects that have non-specific cancer types as well as a cumulative total of our investment in cancer types that received less than 4% of our 2019 funding, including cervical cancers, gastrointestinal cancers, head and neck cancers, melanomas and sarcomas.

Number of Projects by Cancer Type

Types



Types




[†]Our projects are interdisciplinary by design and often apply to more than one cancer type. Our investment per cancer type is an estimation. The interdisciplinary nature of our projects also means that the number of projects by cancer type should not be added, as their sum will be more than 47, the number of projects we currently fund.


CANCER TOPICS[†]

Investment by Cancer Topic

● Precision Medicine	\$7.6M
● Cancer Biology	\$6.4M
● Immunotherapy	\$3.2M
● Cancer Metastasis	\$2.8M
● New Technologies	\$1.9M
● Biobanking	\$1.6M
● Cancer Drugs	\$1.5M
● Early Detection & Diagnosis	\$946K
● Chemotherapy & Radiation	\$333K
● Cancer Prevention	\$318K



Number of Projects by Cancer Topic



[†]Our projects are interdisciplinary by design and often apply to more than one cancer topic. Our investment per cancer topic is an estimation. The interdisciplinary nature of our projects also means that the number of projects by cancer topic should not be added, as their sum will be more than 47, the number of projects we currently fund.

YEAR-TO-YEAR COMPARISON



2017 – 2018 Fiscal Year

The differences in numbers for projects, researchers and institutions between the two fiscal years (2017-18 shown here and 2018-19 shown at the top of the infographic) reflect new developments at TFRI as well as the regular changes that come with our annual research operations and funding cycles.

TFRI is now focused on creating an initiative to accelerate precision medicine, known as the Marathon of Hope Cancer Centres Network. In preparation for the launch of the new network, over the last year TFRI has funded pilot projects that bring together multiple institutions within a region. This explains why a smaller number of individual projects has been funded, while there has been an increase in funded researchers and in partner institutions.

Additionally, as part of our operational cycle, some projects have been completed and their funding term has ended. Our research investment total varies annually and is based on funds received from The Terry Fox Foundation and other funders.